# STARTRK-2 (NCT02568267)

> Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

No report yet. It can be ordered.

- Drugs tested: entrectinib
- Indication: advanced NTRK1/2/3, ROS1 or ALK fusion-positive solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02568267
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Hoffmann-La Roche
- Conditions: Breast Cancer; Cholangiocarcinoma; Colorectal Cancer; Head and Neck Neoplasms; Lymphoma, Large-Cell, Anaplastic; Melanoma; Neuroendocrine Tumors; Non-Small Cell Lung Cancer; Ovarian Cancer; Pancreatic Cancer; Papillary Thyroid Cancer; Primary Brain Tumors; Renal Cell Carcinoma; Sarcomas; Salivary Gland Cancers; Adult Solid Tumor
- Interventions: Entrectinib
- Enrollment: 534
- Primary outcome: Objective Response Rate

## Indexed commentary on STARTRK-2 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 10
- Podcasts: 3
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=startrk-2-nct02568267

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02568267", "email": "<work email>"}; the inbox owner confirms by the emailed link.